Infectious Disease General
RSSArticles
-
Molnupiravir vs. Nirmatrelvir-Ritonavir for Early Symptomatic COVID-19
A randomized, controlled, multicenter Phase II clinical trial compared molnupiravir, ritonavir-boosted nirmatrelvir, or no drug for low-risk adult patients ages 18-50 years with symptomatic COVID-19. Viral clearance was 84% faster with ritonavir-boosted nirmatrelvir and 37% faster with molnupiravir compared to no treatment.
-
Infectious Disease Alert Updates
Smallpox Vaccination Effective Against Mpox; CLABSI Prevention
-
Rocky Mountain Spotted Fever: California and Mexico
The Centers for Disease Control and Prevention alerts clinicians to cases of Rocky Mountain spotted fever in southern California that had been acquired in Mexico.
-
Comparing Adjuvant Clindamycin to Linezolid for Invasive Group A Streptococcal Infections
In a retrospective, single-center cohort study of patients with severe group A streptococcal infection, there was no significant difference in clinical response in those treated with adjunctive clindamycin as compared with adjunctive linezolid
-
Imported Gestational Malaria
Pregnant women can develop malaria in non-endemic areas, even when they are far removed from malaria exposure both geographically and temporally.
-
ID Consultation Leads to Reduced Mortality from Gram-Negative Bacteremia
A multicenter, retrospective cohort study on patients with gram-negative bacteremia found infectious diseases consultation was associated with a 40% decrease in 30-day mortality.
-
2024 Resolution: Not to Be Replaced by a Machine
Chatbots, such as ChatGPT, are thought to have potential to eventually replace some straightforward infectious disease consultations. However, current technology does not yet instill confidence that the use of chatbots will be adequately accurate or safe for complex patient care. In addition, philosophical and ethical constraints raise doubt about the value of replacing specialist physician consultations.
-
Taming of the Flu: A 2023 Update on What Is New
The 2023-2024 influenza season is already among us, and healthcare practitioners on the frontline must have current knowledge of prevention and treatment strategies, particularly in our nation’s emergency departments.
-
Infectious Disease Alert Updates
Peak SARS-CoV-2 Viral Loads Delayed; Should MRSA Require Isolation and Contact Precautions?
-
Sulbactam-Durlobactam for Treatment of Bacterial Pneumonia
Sulbactam-durlobactam is non-inferior to colistin in the treatment of serious bacterial infections caused by Acinetobacter baumannii-calcoaceticus complex organisms.